Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.30 |
| ▸ | BHMT | Q93088 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234510 | 0.80 | ALDH1A1 (0.54) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL2875767 | 0.80 | ALDH1A1 (0.54) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL6555262 | 0.80 | ALDH1A1 (0.54) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL6501684 | 0.80 | ALDH1A1 (0.54) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL12438551 | 0.80 | ALDH1A1 (0.54) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL7418366 | 0.78 | ALDH1A1 (0.52) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL7876560 | 0.78 | ALDH1A1 (0.52) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL7184921 | 0.78 | ALDH1A1 (0.52) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL18738130 | 0.76 | ALDH1A1 (0.50) | PTGS1ALDH1A1MAPTKIF11SLC7A5 | |
| SCHEMBL21443801 | 0.76 | ALDH1A1 (0.50) | PTGS1ALDH1A1MAPTKIF11SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-11-04 | — | — | US | disclosed |
| US-20210322388-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| WO-2008101231-A2 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | PTGS1 3860/4885ALDH1A1 4601/4885MAPT 3275/4885 |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | PTGS1 2752/4885ALDH1A1 931/4885MAPT 2888/4885 |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 3928/4885ALDH1A1 2290/4885MAPT 1738/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | PTGS1 2442/4885ALDH1A1 661/4885MAPT 3359/4885 |
| US-20210322388-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | PTGS1 4689/4885ALDH1A1 247/4885MAPT 1826/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | PTGS1 3777/4885ALDH1A1 4606/4885MAPT 2170/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | PTGS1 4023/4885ALDH1A1 2843/4885MAPT 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.